Osborne Clarke advised UCL Technology Fund on the investment. Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has advised Nexeon on the deal. Nexeon was granted significant US$80 million investment from a consortium including SKC Co. Ltd (SKC), SJL Partners LLC...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has advised the shareholders and management team of Western Global on the deal. With MML’s support, Western Global will continue its strong growth trajectory...
You must be a Standard 1 Year member to access this content.
